Skip to main content

Table 3 Baseline characteristics of the restenosis and non-restenosis group

From: Post-tuberculosis tracheobronchial stenosis: long-term follow-up after self-expandable metallic stents placement and development of a prediction score—the Restenosis Score

Characteristics

Restenosis group (N = 29)

Non-restenosis group (N = 48)

Gender

 Male (%)

7 (24.1)

12 (25.0)

 Female (%)

22 (75.9)

36 (75.0)

Age (mean ± SD, years)

30.31 ± 8.99

34.25 ± 11.49

Location

 Left main bronchus (%)

26 (89.7)

39 (81.3)

 Right main bronchus (%)

2 (6.9)

5 (10.4)

 Bronchus intermedius (%)

1 (3.4)

4 (8.3)

Stent involved

 SEMS (Nanjing Micro-Tech, China) (%)

19 (65.5)

26 (54.2)

 Ultraflex SEMS (Boston Scientific, USA) (%)

10 (34.5)

22 (45.8)

Stenosis type

 Scarring (%)

10 (34.5)

20 (41.7)

 Bronchomalacia (%)

2 (6.9)

13 (27.1)

 Mixed (%)

13 (44.8)

13 (27.1)

 Bronchial atresia (%)

4 (13.8)

2 (4.1)

Number of pre-stenting interventions

164

179

 Thermal ablation

34 (20.7)

26 (14.5)

 Balloon dilation

124 (75.6)

153 (85.5)

 Cryotherapy

6 (3.7)

0 (0.0)

Median duration of implantation (mean ± SD, months)

132.38 ± 64.05

164.17 ± 44.00

Neo-epithelialization (%)

16 (55.2)

41 (85.4)

Complications

 Granulation tissue (%)

26 (89.7)

23 (47.9)

 Scarring tissue (%)

15 (51.7)

3 (6.3)

 Sputum retention (%)

3 (10.3)

2 (4.2)

 Necrotic tissue (%)

0 (0.0)

1 (2.1)

 Stent breakage (%)

0 (0.0)

2 (4.2)

 Infection (%)

0 (0.0)

1 (2.1)

Outcomes

 Stability (%)

4 (13.8)

45 (93.8)

 Still under treatment (%)

12 (41.4)

0 (0.0)

 Bronchial atresia (%)

11 (37.9)

0 (0.0)

  Surgery (%)

9 (81.8)

0 (0.0)

 Lost follow-up (%)

2 (6.9)

3 (6.2)